Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 21:167-178, 2002.
Abrams P, Hanno P, Wein P. Overactive bladder and painful bladder syndrome: there need not be confusion. Neurourology and Urodynamics 24:149-150 (2005).
Abrams P. Describing bladder storage function: overactive bladder syndrome and detrusor overactivity.Urology. 2003 Nov;62(5 Suppl 2):28-37; discussion 40-2.
Abrams P, Swift S. Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis. Eur Urol. 2005 Sep;48(3):483-7.
Brubaker L. Urgency: the cornerstone symptom of overactive bladder.Urology 2004;64(Suppl 1):12-6 [PMUI: 15621222]
Bulmer P, Abrams P. The unstable detrusor. Urol Int 2004;72:1-12 [PMUI: 14730158]
Chapple CR, Artibani W, Cardozo LD, et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int 2005;95:335-40
Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J; for the STAR study group. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial.Eur Urol. 2005 Sep;48(3):464-70.
Chapple CR, Abrams P. Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow.Eur Urol. 2005 Jul;48(1):102-9.
Chu FM, Dmochowski R. Pathophysiology of Overactive Bladder. Am J Med 2006;119 (Suppl 1):3-8.
De Groat WC. A neurologic basis for the overactive bladder. Urology 50 (suppl 6A): 36-52,1997.
FitzGerald MP, Kenton KS, Brubaker L. Localization of the urge to void in patients with painful bladder syndrome. Neurourol Urodyn 24:633-637 (2005)
Foote J , Glavind K , Kralidis G , Wyndaele JJ . Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. Eur Urol. 2005 Sep;48(3):471-7.
Hanno PM, Landis R, Matthews-Cook Y et al, for the Interstitial Cystitis Database Study Group: The diagnosis of interstitial cystitis revisited: lessons learned from the National Institutes of Health Interstitial Cystitis Database Study. J Urol 161:553-557, 1999.
Hill S, Khullar V, Wyndaele JJ, Lheritier K. Dose response with darifenacin, a novel once-daily M(3) selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. Int Urogynecol J Pelvic Floor Dysfunct. 2005 Jul 6;
Holstege G. Micturition and the soul. J Comp Neurol. 2005 Dec 5;493(1):15-20.
Homma Y , Yamaguchi O , Hayashi K . An epidemiological survey of bladder symptoms in Japan.BJU Int. 2005 Dec;96(9):1314-1318.
Hu TW, Wagner TH. Health-related consequences of overactive bladder: an economic perspective.BJU Int. 2005 Sep;96 Suppl 1:43-5.
Kavia R, Mumtaz F. Overactive bladder.J R Soc Health. 2005 Jul;125(4):176-9.
Kay GG, Granville LJ. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly.Clin Ther. 2005 Jan;27(1):127-38; quiz 139-40.
McGrother CW, Donaldson MM, Hayward T, Matthews R, Dallosso HM, Hyde C. Urinary storage symptoms and comorbidities: a prospective population cohort study in middle-aged and older women.Age Ageing. 2005 Oct 18;
Minaglia S, Ozel B, Bizhang R, Mishell jr DR. Increased prevalence of interstitial cystitis in women with detrusor overactivity refractory to anticholinergic therapy. Urology 66(4), 2005.
Tubaro A . D efining overactive bladder: epidemiology and burden of disease.Urology 2004;64(Suppl 1):2-6
Palleschi G, Tubaro A, Miano L. Overactive bladder: modulating the effects of antimuscarinic therapy.Minerva Urol Nefrol. 2005 Dec;57(4):237-45.
Sahai A, Khan M, Fowler CJ, Dasgupta P. Botulinum toxin for the treatment of lower urinary tract symptoms: a review.Neurourol Urodyn. 2005;24(1):2-12.
Scheife R, Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly.Clin Ther. 2005 Feb;27(2):144-53.
Schulte-Baukloh H, Weiss C, Stolze T, Herholz J, Sturzebecher B, Miller K, Knispel HH. Botulinum-A Toxin Detrusor and Sphincter Injection in Treatment of Overactive Bladder Syndrome: Objective Outcome and Patient Satisfaction.Eur Urol. 2005 Dec;48(6):984-990. Epub 2005 Jul 18.
Temml C, Heidler S, Ponholzer A, Madersbacher S. Prevalence of the overactive bladder syndrome by applying the International Continence Society definition.Eur Urol. 2005 Oct;48(4):622-7.
Tomoe H, Sekiguchi Y, Horiguchi M, Toma H. Questionnaire survey on female urinary frequency and incontinence.Int J Urol. 2005 Jul;12(7):621-30.
Wu EQ, Birnbaum H, Marynchenko M, Mareva M, Williamson T, Mallett D. Employees with overactive bladder: work loss burden.J Occup Environ Med. 2005 May;47(5):439-46.
Wyndaele JJ , Van Meel TD, De Wachter S. Detrusor overactivity. Does it represent a difference if patients feel the involuntary contractions? J Urol. 2004 Nov;172(5 Pt 1):1915-8.
Zinner NR. Trospium chloride: an anticholinergic quaternary ammonium compound for the treatment of overactive bladder.Expert Opin Pharmacother. 2005 Jul;6(8):1409-20
Zinner N, Tuttle J, Marks L. Efficacy and tolerability of darifenacin, a muscarinic M(3) selective receptor antagonist (M(3) SRA), compared with oxybutynin in the treatment of patients with overactive bladder.World J Urol. 2005 Sep;23(4):248-52.